In keeping with strategies discussed in its third-quarter financial update (Marketletter October 29), UK drug major GlaxoSmithKline is set to build a L50.0 million ($102.2 million) neuroscience research center in Shanghai, China. The news, which was reported by the Financial Times, forms part of R&D chief Moncef Slaoui's plans for a major shake up of the firm's drug development operations (see page 6). He told the FT that, "for us, China is not about outsourcing and cheap labor," adding that it is not the firm's intention to "give them the crumbs." Instead, he explained that the investment, one of the largest in the country by any of the drug majors, is designed to create "the next seedbed for future discoveries."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze